陈晓菁;杨佳璎;廖关诚;文思敏;舒跃龙;

• 1:中山大学·深圳公共卫生学院(深圳)

摘要(Abstract)：

新型冠状病毒（SARS-CoV-2）疫情在全球持续传播，至今已经演化出多种新冠病毒变异株。关切变异株（Variants of Concern,VOCs）和关注变异株（Variants of Interest,VOIs）具有不同的生物学特性、传播力和致病力，现有疫苗对不同变异株的保护作用以及检测试剂的效能成为公共卫生的关注点。应该建立全球的监测体系，不断跟进变异株对检测效力、疫苗效能及药物作用的影响，及时对防控策略进行调整。

关键词(KeyWords)： 新型冠状病毒(SARS-CoV-2);变异株;疫苗

Abstract:

Keywords:

基金项目(Foundation): 科技部重点研发计划项目新型冠状病毒感染的肺炎疫情应急（项目号：2020YFC0840900）,题目：2019-nCoV基因组变异规律和流行趋势预测研究;; 深圳科技创新委员会项目（项目号：KQTD20180411143323605）,题目：重要传染病精准预警与防治技术体系研发团队（孔雀团队）~~

作者(Authors): 陈晓菁;杨佳璎;廖关诚;文思敏;舒跃龙;

DOI: 10.13242/j.cnki.bingduxuebao.004184

参考文献(References)：

• [1]Klavinskis L S,Liu M A,Lu S. A timely update of global COVID-19 vaccine development[J]. Emerg Microbes Infect,2020,9(1):2379-2380.
• [2]Gómez C E, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19[J]. Vaccines(Basel),2021,9(3).
• [3]Fontanet A,Autran B,Lina B,Kieny M P,Karim S S A,Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic[J]. Lancet,2021,397(10278):952-954.
• [4]https：//www. who. int/en/activities/tracking-SARSCoV-2-variants/.
• [5]Wibmer C K,Ayres F,Hermanus T,Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson B E, de Oliveira T,Vermeulen M,van der Berg K,Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A,Cohen C,Morris L,Bhiman J N,Moore P L. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma[J]. Nat Med,2021,27(4):622-625.
• [6]Weisblum Y,Schmidt F,Zhang F,DaSilva J,Poston D, Lorenzi J C C, Muecksch F, Rutkowska M,Hoffmann H H,Michailidis E,Gaebler C,Agudelo M,Cho A,Wang Z,Gazumyan A,Cipolla M,Luchsinger L,Hillyer C D,Caskey M,Robbiani D F,Rice C M,Nussenzweig M C, Hatziioannou T, Bieniasz P D.Escape from neutralizing antibodies by SARS-CoV-2spike protein variants[J/OL]. Elife, 2020,28(9):e61312.
• [7]Kraemer M U G,Hill V,Ruis C,Dellicour S,Bajaj S,McCrone J T, Baele G, Parag K V, Battle A L,Gutierrez B,Jackson B,Colquhoun R,O'Tooleá，Klein B,Vespignani A,Volz E,Faria N R,Aanensen D M, Loman N J, du Plessis L, Cauchemez S,Rambaut A,Scarpino S V,Pybus O G. Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B. 1.1.7emergence[J]. Science,2021,373(6557):889-895.
• [8]Srivastava S,Banu S,Singh P,Sowpati D T,Mishra R K. SARS-CoV-2 genomics:An Indian perspective on sequencing viral variants[J]. Journal of Biosciences,2021,46(1):22.
• [9]Daniloski Z,Jordan T X,Ilmain J K,Guo X,Bhabha G,tenOever B R,Sanjana N E. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types[J/OL]. Elife,2021,10:e65365.
• [10]Tegally H,Wilkinson E,Giovanetti M,Iranzadeh A,Fonseca V,Giandhari J,Doolabh D,Pillay S,San E J,Msomi N,Mlisana K,Gottberg A V,Walaza S,Allam M,Ismail A,Mohale T,Glass A,Engelbrecht S, Zyl G V, Preiser W, Petruccione F, Sigal A,Hardie D,Marais G,Hsiao M,Korsman S,Davies M,Tyers L,Mudau I,York D,Maslo C,Goedhals D,Abrahams S,Laguda-Akingba O,Alisoltani-Dehkordi A,Godzik A,Wibmer C K,Sewell B,Louren?o J,Alcantara L, Pond S L K, Weaver S, Martin D.Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2(SARSCoV-2)lineage with multiple spike mutations in South Africa.[J/OL]. medRxiv. 2020,6(3):e0035321.
• [11]Chen L L,Lu L,Choi C Y,Cai J P,Tsoi H W,Chu A W,Ip J D,Chan W M,Zhang R R,Zhang X,Tam A R,Lau D P,To W K,Que T L,Yip C C,Chan K H,Cheng V C,Yuen K Y,Hung I F,To K K. Impact of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variant-associated receptor binding domain(RBD)mutations on the susceptibility to serum antibodies elicited by coronavirus disease 2019(COVID-19)infection or vaccination[J]. Clin Infect Dis,2022,74(9):1623-1630.
• [12]Becerra-Flores M,Cardozo T. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate[J/OL].Int J Clin Pract,2020,74(8):e13525.
• [13]Starr T N, Greaney A J, Hilton S K, Ellis D,Crawford K H D,Dingens A S,Navarro M J,Bowen J E,Tortorici M A,Walls A C,King N P,Veesler D,Bloom J D. Deep mutational scanning of SARS-CoV-2receptor binding domain reveals constraints on folding and ACE2 binding[J/OL]. Cell,2020,182(5):1295-1310.e1220.
• [14]Gu H,Chen Q,Yang G,He L,Fan H,Deng Y Q,Wang Y,Teng Y,Zhao Z,Cui Y,Li Y,Li X F,Li J,Zhang N N,Yang X,Chen S,Guo Y,Zhao G,Wang X,Luo D Y,Wang H,Yang X,Li Y,Han G,He Y,Zhou X,Geng S,Sheng X,Jiang S,Sun S,Qin C F,Zhou Y. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy[J]. Science, 2020, 369(6511):1603-1607.
• [15]Liu Z,VanBlargan L A,Bloyet L M,Rothlauf P W,Chen R E,Stumpf S,Zhao H,Errico J M,Theel E S,Liebeskind M J,Alford B,Buchser W J,Ellebedy A H, Fremont D H, Diamond M S, Whelan S P J.Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization[J/OL]. Cell Host Microbe,2021,29(3):477-488.e474.
• [16]Baum A,Fulton B O,Wloga E,Copin R,Pascal K E,Russo V,Giordano S,Lanza K,Negron N,Ni M,Wei Y, Atwal G S, Murphy A J, Stahl N,Yancopoulos G D,Kyratsous C A. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies[J]. Science,2020,369(6506):1014-1018.
• [17]Luan B, Huynh T. Insights into SARS-CoV-2's Mutations for Evading Human Antibodies:Sacrifice and Survival[J]. J Med Chem,2022,65(4):2820-2826.
• [18]Kemp S A,Collier D A,Datir R,Gayed S,Gupta R K. Neutralising antibodies drive Spike mediated SARSCoV-2 evasion[J]. 2020.
• [19]Kemp S A,Collier D A,Datir R P,Ferreira I,Gayed S,Jahun A,Hosmillo M,Rees-Spear C,Mlcochova P,Lumb I U,Roberts D J,Chandra A,Temperton N,Collaboration C-N B C-,Consortium C-G U,Sharrocks K,Blane E,Modis Y,Leigh K E,Briggs J A G,van Gils M J, Smith K G C, Bradley J R, Smith C,Doffinger R,Ceron-Gutierrez L,Barcenas-Morales G,Pollock D D,Goldstein R A,Smielewska A,Skittrall J P,Gouliouris T,Goodfellow I G,Gkrania-Klotsas E,Illingworth C J R,McCoy L E,Gupta R K. SARSCoV-2 evolution during treatment of chronic infection[J]. Nature,2021,592(7853):277-282.
• [20]Meng B,Kemp S A,Papa G,Datir R,Ferreira I,Marelli S,Harvey W T,Lytras S,Mohamed A,Gallo G,Thakur N,Collier D A,Mlcochova P,Consortium C-G U,Duncan L M,Carabelli A M,Kenyon J C,Lever A M, De Marco A, Saliba C, Culap K,Cameroni E,Matheson N J,Piccoli L,Corti D,James L C,Robertson D L,Bailey D,Gupta R K. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70and its role in the Alpha variant B. 1.1.7[J/OL]. Cell Rep,2021,35(13):109292.
• [21]Volkan E. COVID-19:Structural Considerations for Virus Pathogenesis,Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era[J]. Mol Biotechnol,2021:1-13.
• [22]Liu Y,Soh W T,Kishikawa J I,Hirose M,Nakayama E E,Li S,Sasai M,Suzuki T,Tada A,Arakawa A,Matsuoka S,Akamatsu K,Matsuda M,Ono C,Torii S,Kishida K,Jin H,Nakai W,Arase N,Nakagawa A,Matsumoto M,Nakazaki Y,Shindo Y,Kohyama M,Tomii K,Ohmura K,Ohshima S,Okamoto T,Yamamoto M,Nakagami H,Matsuura Y,Nakagawa A,Kato T,Okada M,Standley D M,Shioda T,Arase H. An infectivity-enhancing site on the SARS-CoV-2spike protein targeted by antibodies[J/OL]. Cell,2021,184(13):3452-3466.e3418.
• [23]Davies N G,Abbott S,Barnard R C,Jarvis C I,Kucharski A J,Munday J D,Pearson C A B,Russell T W, Tully D C, Washburne A D, Wenseleers T,Gimma A,Waites W,Wong K L M,van Zandvoort K,Silverman J D,Diaz-Ordaz K,Keogh R,Eggo R M,Funk S,Jit M,Atkins K E,Edmunds W J. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England[J]. Science,2021,372(6538).
• [24]Wise J. COVID-19:The E484K mutation and the risks it poses[J]. BMJ,2021,372:n359.
• [25]Washington N L,Gangavarapu K,Zeller M,Bolze A,Cirulli E T, Schiabor Barrett K M, Larsen B B,Anderson C,White S,Cassens T,Jacobs S,Levan G,Nguyen J, Ramirez J M, 3rd, Rivera-Garcia C,Sandoval E,Wang X,Wong D,Spencer E,RoblesSikisaka R,Kurzban E,Hughes L D,Deng X,Wang C,Servellita V,Valentine H,De Hoff P,Seaver P,Sathe S,Gietzen K,Sickler B,Antico J,Hoon K,Liu J, Harding A, Bakhtar O, Basler T, Austin B,MacCannell D,Isaksson M,Febbo P G,Becker D,Laurent M, McDonald E, Yeo G W, Knight R,Laurent L C,de Feo E,Worobey M,Chiu C Y,Suchard M A, Lu J T, Lee W, Andersen K G.Emergence and rapid transmission of SARS-CoV-2B. 1.1.7 in the United States[J/OL]. Cell,2021,184(10):2587-2594.e2587.
• [26]Sapkal G N,Yadav P D,Ella R,Deshpande G R,Sahay R R,Gupta N,Vadrevu K M,Abraham P,Panda S,Bhargava B. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1.7 variant of SARS-CoV-2[J/OL]. J Travel Med,2021,28(4):taab051. DOI:10.1093/jtm/taab051.
• [27]European Centre for Disease Prevention and Control.SARS-CoV-2-increased circulation of variants of concern and vaccine rollout in the EU/EEA,14th update[EB/OL]. https：//www.readkong.com/page/sars-cov-2-increased-circulation-of-variants-of-concern-and-5199579. 20,Aug,2021.
• [28]Liu C,Ginn H M,Dejnirattisai W,Supasa P,Wang B,Tuekprakhon A,Nutalai R,Zhou D,Mentzer A J,Zhao Y,Duyvesteyn H M E,López-Camacho C,SlonCampos J,Walter T S,Skelly D,Johnson S A,Ritter T G,Mason C,Costa Clemens S A,Gomes Naveca F,Nascimento V,Nascimento F,Fernandes da Costa C,Resende P C,Pauvolid-Correa A,Siqueira M M,Dold C,Temperton N,Dong T,Pollard A J,Knight J C, Crook D, Lambe T, Clutterbuck E, Bibi S,Flaxman A,Bittaye M,Belij-Rammerstorfer S,Gilbert S C,Malik T,Carroll M W,Klenerman P,Barnes E,Dunachie S J,Baillie V,Serafin N,Ditse Z,Da Silva K,Paterson N G,Williams M A,Hall D R,Madhi S,Nunes M C,Goulder P,Fry E E,Mongkolsapaya J,Ren J,Stuart D I,Screaton G R. Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum[J/OL]. Cell,2021,5;184(16):4220-4236.e13.
• [29]Allen H, Vusirikala A, Flannagan J, Twohig KA,Zaidi A,Chudasama D,Lamagni T,Groves N,Turner C,Rawlinson C,Lopez-Bernal J,Harris R,Charlett A, Dabrera G, Kall M; COVID-19 Genomics UK(COG-UK Consortium). Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant(B. 1.617.2):national case-control study.[J/OL]. Lancet Reg Health Eur. 2022,12:100252.
• [30]Baj A,Novazzi F,Ferrante F D,Genoni A,Cassani G, Prestia M, Colombo A, Capuano R, Zago C,Pasciuta R,Tamborini A,Rossi A,Tettamanzi E,Catanoso G, Focosi D, Maffioli L, Maggi F.Introduction of SARS-CoV-2 C. 37(WHO VOI lambda)from Peru to Italy[J]. J Med Virol,2021.
• [31]Nyberg T,Twohig K A,Harris R J,Seaman S R,Flannagan J, Allen H, Charlett A, De Angelis D,Dabrera G,Presanis A M. Risk of hospital admission for patients with SARS-CoV-2 variant B. 1.1.7:cohort analysis[J]. BMJ,2021,373:n1412.
• [32]Song R,Han B,Song M,Wang L,Conlon C P,Dong T,Tian D,Zhang W,Chen Z,Zhang F,Shi M,Li X.Clinical and epidemiological features of COVID-19family clusters in Beijing, China[J/OL]. J Infect,2020,81(2):e26-e30.
• [33]Cele S,Gazy I,Jackson L,Hwa S H,Tegally H,Lustig G,Giandhari J,Pillay S,Wilkinson E,Naidoo Y,Karim F,Ganga Y,Khan K,Bernstein M,Balazs A B,Gosnell B I,Hanekom W,Moosa M S,Lessells R J,de Oliveira T,Sigal A. Escape of SARS-CoV-2501Y.V2 from neutralization by convalescent plasma[J].Nature,2021,593(7857):142-146.
• [34]Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 16[EB/OL]. https：//assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/994839/Variants_of_Concern_VOC_Technical_Briefing_16. pdf. 20,Aug,2021.
• [35]Edara V V,Pinsky B A,Suthar M S,Lai L,DavisGardner M E,Floyd K,Flowers M W,Wrammert J,Hussaini L, Ciric C R, Bechnak S, Stephens K,Graham B S,Bayat Mokhtari E,Mudvari P,Boritz E,Creanga A,Pegu A,Derrien-Colemyn A,Henry A R,Gagne M,Douek D C,Sahoo M K,Sibai M,Solis D,Webby R J,Jeevan T,Fabrizio T P. Infection and vaccine-induced neutralizing-antibody responses to the sars-cov-2 b.1.617 variants[J]. N Engl J Med,2021.
• [36]Zeyaullah M,AlShahrani A M,Muzammil K,Ahmad I,Alam S,Khan W H,Ahmad R. COVID-19 and SARS-CoV-2 Variants:current challenges and health concern[J]. Front Genet,2021,12:693916.
• [37]Campbell F,Archer B,Laurenson-Schafer H,Jinnai Y,Konings F,Batra N,Pavlin B,Vandemaele K,Van Kerkhove M D,Jombart T,Morgan O,le Polain de Waroux O. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June2021[J]. Euro Surveill,2021,26(24).
• [38]Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals[J]. J Infect,2022,84(1):94-118.
• [39]Zhou H,Dcosta B M,Samanovic M I,Mulligan M J,Landau N R,Tada T. B. 1.526 SARS-CoV-2 variants identified in New York city are neutralized by vaccineelicited and therapeutic monoclonal antibodies[J/OL].mBio,2021,12(4):e0138621.
• [40]Annavajhala M K,Mohri H,Wang P,Nair M,Zucker J E, Sheng Z, Gomez-Simmonds A, Kelley A L,Tagliavia M, Huang Y, Bedford T, Ho D D,Uhlemann A C. A novel and expanding SARS-CoV-2variant, B. 1.526, identified in New York[J/OL].medRxiv,2021.
• [41]Kimura I,Kosugi Y,Wu J,Yamasoba D,Butlertanaka E P,Tanaka Y L,Liu Y,Shirakawa K,Kazuma Y,Nomura R,Horisawa Y,Tokunaga K,Takaori-Kondo A,Arase H,The Genotype to Phenotype Japan C,Saito A,Nakagawa S,Sato K. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance[J/OL]. bioRxiv,2021:2007-2028.
• [42]Acevedo M L,Alonso-Palomares L,Bustamante A,Gaggero A, Paredes F, Cortés C P, ValienteEcheverría F, Soto-Rifo R. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda[J]. MedRxiv,2021.
• [43]Khoury D S,Cromer D,Reynaldi A,Schlub T E,Wheatley A K,Juno J A,Subbarao K,Kent S J,Triccas J A, Davenport M P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection[J]. Nat Med,2021,27(7):1205-1211.
• [44]Planas D,Veyer D,Baidaliuk A,Staropoli I,GuivelBenhassine F,Rajah M M,Planchais C,Porrot F,Robillard N,Puech J,Prot M,Gallais F,Gantner P,Velay A,Le Guen J,Kassis-Chikhani N,Edriss D,Belec L, Seve A, Courtellemont L, PéréH,Hocqueloux L,Fafi-Kremer S,Prazuck T,Mouquet H,Bruel T,Simon-Lorière E,Rey F A,Schwartz O.Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization[J]. Nature,2021,596(7871):276-280.
• [45]Shen X,Tang H,McDanal C,Wagh K,Fischer W,Theiler J,Yoon H,Li D,Haynes B F,Sanders K O,Gnanakaran S, Hengartner N, Pajon R, Smith G,Glenn G M,Korber B,Montefiori D C. SARS-CoV-2variant B. 1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines[J/OL]. Cell Host Microbe,2021,29(4):529-539.e523.
• [46]Garcia-Beltran W F,Lam E C,St Denis K,Nitido A D,Garcia Z H,Hauser B M,Feldman J,Pavlovic M N,Gregory D J,Poznansky M C,Sigal A,Schmidt A G,Iafrate A J,Naranbhai V,Balazs A B. Multiple SARS-CoV-2 variants escape neutralization by vaccineinduced humoral immunity[J/OL]. Cell, 2021, 184(9):2372-2383.e2379.
• [47]Wang P,Nair M S,Liu L,Iketani S,Luo Y,Guo Y,Wang M,Yu J,Zhang B,Kwong P D,Graham B S,Mascola J R,Chang J Y,Yin M T,Sobieszczyk M,Kyratsous C A,Shapiro L,Sheng Z,Huang Y,Ho D D. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7[J]. Nature,2021,593(7857):130-135.
• [48]Nasreen S,Chung H,He S,Brown K A,Gubbay J B,Buchan S A,Fell D B,Austin P C,Schwartz K L,Sundaram M E,Calzavara A,Chen B,Tadrous M,Wilson K, Wilson S E, Kwong J C, Canadian ImmunizationResearchNetworkProvincial Collaborative Network I. Effectiveness of COVID-19vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario[J]. Nat Microbiol,2022,7(3):379-385.
• [49]Wu K,Werner A P,Moliva J I,Koch M,Choi A,Stewart-Jones G B E,Bennett H,Boyoglu-Barnum S,Shi W,Graham B S,Carfi A,Corbett K S,Seder R A, Edwards D K. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants[J]. bioRxiv, 2021. DOI:10.1101/2021.01.25.427948. Preprint.
• [50]West A P,Jr.,Wertheim J O,Wang J C,Vasylyeva T I,Havens J L,Chowdhury M A,Gonzalez E,Fang C E,Di Lonardo S S,Hughes S,Rakeman J L,Lee H H, Barnes C O, Gnanapragasam P N P, Yang Z,Gaebler C,Caskey M,Nussenzweig M C,Keeffe J R,Bjorkman P J. Detection and characterization of the SARS-CoV-2 lineage B. 1.526 in New York[J]. Nat Commun,2021,12(1):4886.
• [51]Shen X,Tang H,Pajon R,Smith G,Glenn G M,Shi W,Korber B,Montefiori D C. Neutralization of SARSCoV-2 Variants B. 1.429 and B. 1.351[J]. N Engl J Med,2021,384(24):2352-2354.
• [52]Normark J,Vikstr?m L,Gwon Y D,Persson I L,Edin A, Bj?rsell T, Dernstedt A, Christ W, Tevell S,Evander M, Klingstr?m J, Ahlm C, Forsell M.Heterologous ChAdOx1 nCoV-19 and mRNA-1273Vaccination[J]. N Engl J Med,2021,385(11):1049-1051.
• [53]Lustig Y,Zuckerman N,Nemet I,Atari N,Kliker L,Regev-Yochay G,Sapir E,Mor O,Alroy-Preis S,Mendelson E, Mandelboim M. Neutralising capacity against Delta(B.1.617.2)and other variants of concern following Comirnaty(BNT162b2, BioNTech/Pfizer)vaccination in health care workers, Israel[J]. Euro Surveill,2021,26(26).
• [54]Chen R E,Zhang X,Case J B,Winkler E S,Liu Y,VanBlargan L A, Liu J, Errico J M, Xie X,Suryadevara N,Gilchuk P,Zost S J,Tahan S,Droit L,Turner J S,Kim W,Schmitz A J,Thapa M,Wang D,Boon A C M,Presti R M,O'Halloran J A,Kim A H J,Deepak P,Pinto D,Fremont D H,Crowe J E,Jr.,Corti D,Virgin H W,Ellebedy A H,Shi P Y,Diamond M S. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies[J]. Nat Med,2021,27(4):717-726.
• [55]Collier D A,De Marco A,Ferreira I,Meng B,Datir R P,Walls A C,Kemp S A,Bassi J,Pinto D,SilacciFregni C,Bianchi S,Tortorici M A,Bowen J,Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto M S,Pellanda A F,Garzoni C,Riva A,Elmer A,Kingston N,Graves B,McCoy L E,Smith K G C,Bradley J R,Temperton N,Ceron-Gutierrez L,Barcenas-Morales G,Harvey W,Virgin H W,Lanzavecchia A,Piccoli L,Doffinger R,Wills M,Veesler D,Corti D,Gupta R K. Sensitivity of SARS-CoV-2 B. 1.1.7 to mRNA vaccine-elicited antibodies[J]. Nature, 2021, 593(7857):136-141.
• [56]Tada T,Dcosta B M,Samanovic-Golden M,Herati R S, Cornelius A, Mulligan M J, Landau N R.Neutralization of viruses with European,South African,and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccineelicited antibodies[J]. bioRxiv,2021.
• [57]Sheikh A, McMenamin J, Taylor B, Robertson C.SARS-CoV-2 Delta VOC in Scotland:demographics,risk of hospital admission,and vaccine effectiveness[J].Lancet,2021,397(10293):2461-2462.
• [58]Liu J,Liu Y,Xia H,Zou J,Weaver S C,Swanson K A,Cai H,Cutler M,Cooper D,Muik A,Jansen K U,Sahin U,Xie X,Dormitzer P R,Shi P Y. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants[J]. Nature,2021,596(7871):273-275.
• [59]Ferreira I,Kemp S A,Datir R,Saito A,Meng B,Rakshit P, Takaori-Kondo A, Kosugi Y, Uriu K,Kimura I, Shirakawa K, Abdullahi A, Agarwal A,Ozono S,Tokunaga K,Sato K,Gupta R K,CitiidNihr BioResource Covid-19 Collaboration I S-C-G C,Genotype to Phenotype Japan C. SARS-CoV-2 B.1.617Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion[J]. J Infect Dis,2021,224(6):989-994.
• [60]Hoffmann M,Hofmann-Winkler H,Kruger N,Kempf A,Nehlmeier I,Graichen L,Arora P,Sidarovich A,Moldenhauer A S,Winkler M S,Schulz S,Jack H M,Stankov M V,Behrens G M N,Pohlmann S. SARSCoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination[J]. Cell Rep,2021,36(3):109415.
• [61]Wang G L,Wang Z Y,Duan L J,Meng Q C,Jiang M D,Cao J,Yao L,Zhu K L,Cao W C,Ma M J.Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization[J]. N Engl J Med,2021,384(24):2354-2356.
• [62]Li X N,Huang Y,Wang W,Jing Q L,Zhang C H,Qin P Z,Guan W J,Gan L,Li Y L,Liu W H,Dong H,Miao Y T,Fan S J,Zhang Z B,Zhang D M,Zhong N S. Efficacy of inactivated SARS-CoV-2vaccines against the Delta variant infection in Guangzhou:A test-negative case-control real-world study[J]. Emerg Microbes Infect,2021:1-32.
• [63]Huang B,Dai L,Wang H,Hu Z,Yang X,Tan W,Gao G F. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines[J]. 2021.
• [64]Jeewandara C, Aberathna I S, Pushpakumara P D,Kamaladasa A,Guruge D,Jayathilaka D,Gunasekara B, Tanussiya S, Kuruppu H, Ranasinghe T,Dayarathne S,Dissanayake O,Gamalath N,Ekanayake D, Jayamali M, Wijesinghe A, Dissanayake M,Madusanka D, Jayadas T T, Mudunkotuwa A,Somathilake G,Harvie M,Nimasha T,Danasekara S,Wijayamuni R,Schimanski L,Tan T K,Dong T,Townsend A,Ogg G S,Malavige G N. Antibody and T cell responses to Sinopharm/BBIBP-CorV in na?ve and previously infected individuals in Sri Lanka[J/OL].medRxiv,2021.
• [65]Madhi S A,Baillie V,Cutland C L,Voysey M,Koen A L,Fairlie L,Padayachee S D,Dheda K,Barnabas S L,Bhorat Q E,Briner C,Kwatra G,Ahmed K,Aley P,Bhikha S,Bhiman J N,Bhorat A E,du Plessis J,Esmail A,Groenewald M,Hor